Eli Lilly and Company

Eli Lilly and Company's next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Eli Lilly and Company has 891.50M shares outstanding.

As of June 30, 2026, Eli Lilly and Company maintains a current ratio of 1.35, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 162.07, indicating elevated leverage, while an interest coverage ratio of 198.95 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Eli Lilly and Company posted a return on equity (ROE) of 102.44, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 34.73 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.97, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 36.53, useful for judging operating efficiency across full business cycles. The company generates approximately 1.62M in revenue per employee across its workforce of 49,250.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.95 indicates how many times Eli Lilly and Company sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Eli Lilly and Company recorded 6.88B in income tax expense. That works out to an effective tax rate of 20.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 33.60B, leaving 26.71B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Eli Lilly and Company generated 79.67B in revenue and converted that into 26.71B in net income, yielding earnings per share of 29.79. EBITDA reached 35.73B, while operating income came in at 39.61B.

As of June 30, 2026, Eli Lilly and Company holds 8.95B in cash and equivalents against 54.91B in total debt, resulting in a net debt position of 45.96B. Total book value stands at 33.88B, with working capital of 16.93B providing operational flexibility.

Eli Lilly and Company produced 28.08B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -14.52B in capital expenditures, free cash flow totaled 13.56B - equivalent to 15.17 per share.

Over the twelve months ended June 30, 2026, Eli Lilly and Company posted a gross margin of 83.40, reflecting its pricing power and cost economics. The operating margin of 49.72 and net profit margin of 33.53 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Eli Lilly and Company paid dividends of 6.47 per share. The dividend payout ratio of 21.66 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Eli Lilly and Company's most recent stock split took place on October 16, 1997 with a 1:2 split ratio.